In a groundbreaking development, scientists have successfully applied CRISPR gene-editing technology in a personalized therapy designed to treat a young boy with a rare and severe genetic disorder affecting his liver. The study, published on May 15 in the New England Journal of Medicine and presented at the American Society of Gene and Cell Therapy, marks a major step forward in the use of gene editing beyond blood disorders like sickle-cell anemia.
The treatment was developed for KJ, a child born with mutations that impair his liver’s ability to break down proteins properly, leading to dangerous ammonia buildup in his body. This condition, known as urea cycle disorder, can cause severe brain damage and developmental delays. The research was led by Dr. Kiran Musunuru of the University of Pennsylvania and Dr. Rebecca Ahrens-Nicklas from the Children’s Hospital of Philadelphia, who collaborated with several biotech companies to create a therapy tailored specifically to KJ’s unique genetic mutation.
Unlike previous CRISPR therapies approved by the U.S. Food and Drug Administration that involve editing a patient’s blood cells outside the body and reinfusing them, KJ’s treatment involved direct delivery of gene-editing components into his liver cells. The therapy used CRISPR to precisely correct a single faulty base pair in KJ’s DNA, restoring the gene’s normal function.
The gene-editing drug was administered in three doses, starting when KJ was six months old. While it is still early to fully assess the therapy’s effectiveness, initial signs are promising. KJ’s mother, Nicole Muldoon, reported notable developmental progress since starting treatment, contrasting with earlier grim expectations that included comfort care or liver transplant due to the severity of his condition.
Because a liver biopsy would be too risky, researchers are monitoring KJ’s ammonia levels and related metabolic markers to gauge improvement. “He had the most severe form of the disease and is doing better than anticipated,” said Dr. Ahrens-Nicklas.
This bespoke therapy required nearly two years of collaboration between academic researchers and companies specializing in gene editing components and delivery systems. The effort was supported by the Innovative Genomics Institute, founded by CRISPR pioneer Jennifer Doudna.
Researchers are hopeful this case will pave the way for expanding CRISPR-based treatments to other rare genetic diseases, shortening development times and increasing accessibility. “This is the future of medicine,” said Dr. Musunuru. “We are showing it’s possible to make personalized gene-editing therapy in real time and hope no patient will suffer from correctable genetic errors in the future.”
The success of KJ’s treatment signals a new era in precision medicine, where tailored gene therapies offer hope for previously untreatable rare diseases.
